

## 12288 COMPETITIVE PROBLEMS IN THE DRUG INDUSTRY

4. WHEREAS, It is appropriate that decisions with regard to the choice of drug products be made by the health professional possessing the greatest amount of information involved in the particular selection in question, with the attendant accountability, therefore be it

5. RESOLVED, That the physician, having selected the chemical entity to be used for therapy, should be required either to delegate to the pharmacist, or explicitly to retain to himself, selection of the particular drug product to be dispensed and received by the patient.

Washington, D. C.  
25 October 1974

This resolution was approved by the DRB at its regular fall meeting 25 October 1974. Thirteen of the 14 members present at that meeting voted in favor of the resolution. The fourteenth member, Dr. Richard Crout, abstained because of his position as Director of the Bureau of Drugs of the FDA (Food and Drug Administration).

The chronology of the seven formal meetings involved in the development and promulgation of the resolution was as follows:

- 1) 11 July 1973 - At an executive meeting between representatives of the DRB and of the PMA (Pharmaceutical Manufacturers Association) it was suggested that the DRB might review existing drug antisubstitution legislation, with a view to endorsing existing legislation and strengthening the stand against attempts to change it.
- 2) 30 November 1973 - At another executive session of DRB and PMA representatives a draft resolution was passed which strongly endorsed existing antisubstitution laws.
- 3) 25 March 1974 - The draft resolution was presented to the full DRB at its regular spring meeting. During the discussion the liaison representative of the APhA (American Pharmaceutical Association) to the DRB objected on two grounds: that the DRB misunderstood the position of the APhA on drug prescribing and dispensing, and that the APhA had not had an opportunity to present its case, while the PMA had. Chairman of the DRB appointed two representatives from DRB, Dr. Hugh Hussey of the AMA (American Medical Association) and myself to meet as an ad hoc committee with representatives from the APhA.